Share: Facebook Twitter LinkedIn
Activity Provided By:

EXCEL Continuing Education

Emerging Developments in the Treatment of Generalized Myasthenia Gravis

Access Activity

Overview / Abstract:

This activity will address the current treatment landscape as it compares to clinical trials in development focusing on FcRn modulation as a therapeutic target for myasthenia gravis (MG). We will review FcRn inhibitor therapeutic agents and discuss how these therapies may effectively change the management of patients with MG.

Expiration

Jun 16, 2022

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Format

Online, Webinar / Webcast / Video

Credits / Hours

1 AMA/PRA Cat 1 Credit

Accreditation

ACCME

Presenters / Authors / Faculty

Gil I. Wolfe, MD, FAAN
Irvin and Rosemary Smith Professor and Chairman
Department of Neurology
Jacobs School of Medicine and Biomedical Sciences
University at Buffalo/SUNY
Buffalo, NY

Sponsors / Supporters / Grant Providers

argenx Pharmaceuticals

Keywords / Search Terms

EXCEL Continuing Education myasthenia gravis, generalized myasthenia gravis, neurology, ophthalmology, neuromuscular, FcRn inhibition, IgG anitbodies. Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map